[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Corewell Health West\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":167},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,39,68,92,116,140],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100645218","the-systemic-nature-of-severe-traumatic-brain-injury-100645218",false,"NCT07679126","The Systemic Nature of Severe Traumatic Brain Injury","The Systemic Nature of Severe Traumatic Brain Injury: Multi-Omic Analysis of Neural Trauma, Autoantibodies and the Gut-Brain Axis: The MANTRA Study","MANTRA","Inclusion Criteria:\n\n* All patients must be between the ages of 18 to 65 at time of enrollment\n* Study group cohort will consist of at least 20 patients admitted with severe TBI, defined as a GSC less than or equal to 8 with evidence of intracranial pathology on imaging.\n* Trauma control cohort will include at least 10 patients matched on demographics and injury patterns without traumatic brain injury.\n* Healthy control cohort will be comprised of 10 patients without acute traumatic injury or illness, matched to the sTBI patients based on demographics and medical comorbidities.\n\nExclusion Criteria:\n\n* Pregnant Patients\n* Prisoners\n* Patients less than 18 years of age or greater than 65 years of age\n* Patients with a penetrating brain injury mechanism, known neurodegenerative or psychiatric disorders, prior known traumatic brain injury, intracranial neoplasm, patients receiving massing transfusion or blood products prior to arrival, terminal illness or not expected to survive, confirmed or suspected brain death, known autoimmune or immunological condition, receiving immunosuppressant or immunomodulatory therapies, having a cardiac event leading to the injury, or for whom consent is unable to be obtained.",true,"ALL","18 Years","65 Years",{"count":22,"type":23},40,"ESTIMATED","OBSERVATIONAL","Severe Traumatic brain injury (sTBI) is a very serious problem, and right now, doctors don't have special treatments to help stop additional injury. Previous studies showed that when a young person gets this kind of brain injury, their body's defense system reacts quickly and strongly. This can cause problems with the brain's protective barrier breaking down and the body making antibodies that attack its own cells. We think that changes in how the brain and the gut (the part of your body that digests food) talk to each other might make these defense reactions stronger. This study wants to figure out exactly how brain injuries change the gut and how that affects the body's defenses. To do this, we will use new ways to study body chemicals and genes \\[RNA, cell free DNA (cfDNA) and blood chemistry\\] to help us learn why the body reacts this way and how it can lead to more brain injuries and problems in adults with serious brain injuries.",[27],"Severe Traumatic Brain Injury","NOT_YET_RECRUITING","2026-06-25",{"date":31,"type":32},"2026-07-01","ACTUAL",{"date":31,"type":23},{"date":35,"type":23},"2029-07-01",{"name":37,"class":38},"Corewell Health West","OTHER",{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":18,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100598791","phase-4-vascular-trial-associated-registry-pilot-100598791","NCT07076082","Vascular Trial Associated Registry Pilot","Vascular Trial Associated Registry Pilot: Antiplatelet Therapies for Patients Undergoing Lower Extremity Endovascular Revascularization","VSTAR-P","Inclusion Criteria:\n\n* Age greater than or equal to 45 at time of enrollment\n* Patient is scheduled for a PVI or has recently had a PVI in the last 30 days\n* Patient data is being submitted to Fivos, who is acting as the data collection subcontractor for the VQI-PVI registry.\n* Atherosclerotic vascular disease\n\nExclusion Criteria:\n\n* Patients who cannot consent for themselves\n* Allergy to Clopidogrel\n* Patients unable to stop clopidogrel for other medical reasons\n* Patients on dual pathway inhibition (DPI) with low dose rivaroxaban (2.5mg twice a day) that are unable to stop these medications\n* Allergy to aspirin\n* Nonatherosclerotic vascular disease\n* Patients undergoing open bypass at the same time as the peripheral transcutaneous angioplasty\n* Patients with high bleeding risk (HBR) defined as:\n\n  * History of major bleeding, active bleeding disorder, severe renal impairment (CrCl \\\u003C30), concurrent anticoagulation, platelet count \\\u003C100,000\n  * Recent stroke (within 6 months)\n  * Current warfarin therapy or full dose therapeutic direct oral anticoagulants (DOAC).\n* Patients unwilling or unable to comply with standard of care follow-up visits\n* Pregnant women\n* Prisoners","45 Years",{"count":49,"type":23},350,"INTERVENTIONAL",[52],"PHASE4","The purpose of this investigator-initiated, multicenter, open label, randomized trial is to evaluate 1 month vs. 6 months of dual antiplatelet therapy (DAPT) in patients undergoing lower extremity endovascular revascularization. We hypothesize that extending dual antiplatelet therapy (DAPT) to six months, compared to one month, will improve patency rates of target vessels following peripheral vascular intervention (PVI) without significantly increasing complications, particularly bleeding events.",[55],"Peripheral Arterial Disease",[57],"Peripheral Vascular Disease (PVD), Peripheral Vascular Intervention (PVI), Dual Antiplatelet therapy (DAPT), Peripheral Arterial Disease (PAD)","RECRUITING","2026-04-08",{"date":61,"type":32},"2026-04-13",{"date":63,"type":32},"2025-10-15",{"date":65,"type":23},"2028-10-30",{"name":37,"class":38},2,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":50,"phases":78,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},"100351970","intra-corporeal-anastomosis-result-in-quicker-return-of-bowel-functionearlier-discharge-100351970","NCT03862781","Intra-Corporeal Anastomosis Result in Quicker Return of Bowel Function\u002FEarlier Discharge","Randomized Trial of Intra-Corporeal Anastomosis for RighT Colectomies (RICART Study)","RICART","Inclusion Criteria:\n\n* Eligible patients are those over 18 years of age who are regularly scheduled to undergo a right hemicolectomy via a minimally invasive approach (robotic or laparoscopic) with the creation of an anastomosis. Right colectomy will be defined as removal of the ascending colon, ligation of the ileocolic artery and vein, +\u002F- removal of the terminal ileum, +\u002F- removal of the proximal transverse colon, and +\u002F- removal of the right branch of the middle colic artery and vein.\n\nExclusion Criteria:\n\n* Pregnant women\n* Additional colon resection is planned (i.e. left colectomy or proctectomy)\n* Vulnerable populations such as prisoners or adults unable to give consent\n* If the scheduled surgery is planned at Butterworth hospital (as to standardize the nursing care received postoperatively)\n* Emergent cases\n\nPatients will be excluded from the study intra-operatively if:\n\n* The procedure is converted to an open resection\n* If a loop ileostomy is performed in addition to the right colectomy",{"count":77,"type":23},125,[79],"NA","Adult patients who are regularly scheduled to undergo a right hemicolectomy via a minimally invasive approach (robotic or laparoscopic) with the creation of an anastomosis.",[82],"Colorectal Disorders","2026-01-20",{"date":85,"type":32},"2026-01-21",{"date":87,"type":32},"2019-01-28",{"date":89,"type":23},"2027-12",{"name":37,"class":38},1,{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":98,"enrollmentInfo":99,"targetDuration":101,"studyType":24,"phases":4,"briefSummary":102,"conditions":103,"keywords":105,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":91},"100608135","effect-of-hernia-sac-excision-on-crural-tension-in-paraesophageal-hernia-repair-100608135","NCT07197619","Effect of Hernia Sac Excision on Crural Tension in Paraesophageal Hernia Repair","Inclusion Criteria:\n\n* All patients age 18-80 undergoing elective or emergent paraesophageal hernia repair for symptomatic paraesophageal hernia will be eligible for enrollment into the study.\n\nExclusion Criteria:\n\n* Patients with previous history of esophageal, gastric, diaphragmatic, or anti-reflux surgery will be excluded.","80 Years",{"count":100,"type":23},42,"30 Days","Paraesophageal hernia can cause significant clinical symptoms, including reflux, chest pain, nausea, regurgitation, and even life threatening conditions such as bowel obstruction, and gastric volvulus. Repair of a paraesophageal hernia is associated with significant recurrence rate, with primary repair often in excess of 50%. Hernia recurrence and revisional surgery significantly increase the likelihood of complications and decreased quality of life.",[104],"Paraesophageal Hernia",[106,107],"Paraesophageal","Hernia","2025-09-22",{"date":110,"type":32},"2025-09-29",{"date":112,"type":32},"2021-08-27",{"date":114,"type":23},"2026-06",{"name":37,"class":38},{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":50,"phases":124,"briefSummary":125,"conditions":126,"keywords":128,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":91},"100606013","hyperbaric-oxygen-treatment-for-necrotizing-fasciitis-and-necrotizing-soft-tissue-infections-100606013","NCT07170020","Hyperbaric Oxygen Treatment for Necrotizing Fasciitis and Necrotizing Soft Tissue Infections","Inclusion Criteria:\n\n* Age: 18 years old\n* Patients with documented necrotizing fasciitis or necrotizing soft tissue infection as assessed during initial bedside evaluation, in conjunction with available laboratory values, imaging showing gas in soft tissues consitent with necrotizing infection, or surgical debridement of necrosis of fascia, muscle, and variable levels of soft tissue involvement\n* Patient or advocate is able to sign consent\n\nExclusion Criteria:\n\n* Pediatric patients\n* Pregnant patients\n* Patients deemed unlikely to survive or unable to go to surgical debridement",{"count":123,"type":23},160,[79],"The goal of this clinical trial is to learn if hyperbaric oxygen is beneficial in treating necrotizing infections and decreasing rates of morbidity and mortality. This study therefore has two aims:\n\n1. Determine if hyperbaric oxygen improve morbidity and mortality compared to standard of care using a prospective model.\n2. Determine if faster diagnosis to debridement times negate the need for hyperbaric oxygen treatments in necrotizing infections.",[127],"Necrotizing Fascitis",[129,130,131],"necrotizing","fascitis","hyperbaric","2025-09-10",{"date":134,"type":32},"2025-09-12",{"date":136,"type":23},"2025-11-14",{"date":138,"type":23},"2027-11-14",{"name":37,"class":38},{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":50,"phases":148,"briefSummary":149,"conditions":150,"keywords":152,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":91},"100515083","roux-en-y-gastric-bypass-versus-loop-gastrojejunostomy-for-malignant-gastric-outlet-obstruction-100515083","NCT05986890","Roux-en-Y Gastric Bypass Versus Loop Gastrojejunostomy for Malignant Gastric Outlet Obstruction","Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form.\n2. Stated willingness to comply with all study procedures and availability for the duration of the study.\n3. Male or female aged ≥18 years old.\n4. Patients with a diagnosis of malignant gastric outlet obstruction. i. Defined as malignant cancer growth of any organ origin in the area of the distal stomach or duodenum preventing normal gastric emptying as determined by symptoms and cross-sectional imaging studies.\n\n   ii. Symptoms can include abdominal distention, abdominal pain, nausea and vomiting.\n\n   iii. Cross sectional imaging findings can include tumor growth in the area of the distal stomach or duodenum, gastric distention, fluid filled stomach and decompressed bowel distal to obstruction point.\n5. Patients deemed to benefit from surgical bypass as opposed to stent placement, by the primary surgeon. This includes assessing participants survival chances and ability to undergo a surgical procedure.\n6. Patients in a general health status that permits abdominal surgery under general anesthesia. As determined by primary surgeon and anesthesiologist.\n\nExclusion Criteria:\n\n1. Patients that have had previous treatment for malignant gastric outlet obstruction.\n\n   a. Including any previous surgery or stent placement for MGOO\n2. Patients with MGOO deemed to benefit more from endoscopic stent placement rather than surgery for symptom relief. This assessment will be at treating surgeon's discretion.",{"count":147,"type":23},16,[79],"This study is intended to investigate whether roux-en-y bypass surgery is superior to conventional loop gastrojejunostomy for Malignant gastric outlet obstruction in terms of tolerance to solid food intake. We hypothesize that roux-en-y bypass will be associated with improved solid food intake in the first 30 days after surgery.",[151],"Malignant Gastric Outlet Obstruction",[153,154,155,156,157,158],"MGOO","Malignant gastric outlet obstruction","gastric outlet","malignant tumor","proximal bowel obstruction","bowel obstruction","2025-06-13",{"date":161,"type":32},"2025-06-17",{"date":163,"type":32},"2023-08-17",{"date":165,"type":23},"2026-12-01",{"name":37,"class":38},""]